The Epigenetics Team at ChemPartner is led by senior scientists with broad assay development experience. To date, we have had nearly 100 epigenetic enzyme assays, which have been developed and optimized in-house to provide our partners with fast delivery, flexible target selection, and high-quality data. We have diverse technology platforms including TR-FRET, AlphaLISA, Caliper mobility shift and radiometric assay for compound profiling, selectivity panels, mechanism of action studies and HTS. The targets encompass all classes including HKMT, HRMT, HKDM, HDAC, HAT, Bromodomain, Methyl reader and DNMT, among others. We continuously expand our offering in this exciting area.
ChemPartner is well-equipped with a variety of cell-based assays including Histone H3 Methyltransferase, which enables us to examine epigenetic target engagement and the functional consequences in cells. We continually expand the scope of our technologies, including BacMan/GFP/TR-FRET so we are always on the forefront of epigenetics research.
In addition to the in vitro assays, we have also established over 100 xenograft models, many of which can be used in epigenetics studies. For instance, the SETDB1, CARM1 can be applied in breast cancer, and Ezh2, LSD1 for prostate cancer. These models have been used in compound testing for efficacy studies and PK/PD correlation.